CT有助于在合并肺结核分枝杆菌病的类风湿关节炎中提供检测与治疗选择:来自FIRST登记研究
在FIRST登记研究中,4447例类风湿关节炎患者在接受分子靶向治疗前进行胸部CT,107例疑似肺非结核分枝杆菌病、33例经培养确诊,其中14例平片无异常;31例联合抗NTM治疗,28例随访24个月,PNTM组与非PNTM组24个月药物留存率和RA疾病活动度无显著差异,PNTM组无患者病情加重。
要点
- RA患者启动分子靶向治疗前胸部CT可检出平片无法发现的疑似PNTM病。
- 4447例中107例疑似PNTM、33例培养确诊,其中14例平片无异常。
- 31例联合抗NTM治疗,28例随访24个月,PNTM组无病情加重。
核心结论
- 在分子靶向治疗开始前进行CT筛查可检出平片无法发现的疑似无症状肺非结核分枝杆菌病。
- 分子靶向治疗联合抗NTM治疗似乎可控制PNTM病和RA的疾病活动度。
研究设计与样本
- 在Further Improvement of Rheumatoid arthritis Treatment登记研究中,类风湿关节炎患者在引入分子靶向治疗前接受胸部CT。
- 主要终点为CT检出的合并RA的肺非结核分枝杆菌病患者数。
主要发现
- 4447例接受胸部CT的RA患者中,107例疑似PNTM病,33例经培养确诊。
- 33例确诊患者中14例平片无异常,PNTM病仅见于CT扫描。
- 需要分子靶向治疗的RA患者中PNTM病患病率是健康个体的六倍。
- 31例启动分子靶向治疗并联合抗NTM治疗,28例随访24个月。
- PNTM组与非PNTM组24个月药物留存率和RA疾病活动度无显著差异,合并PNTM病未影响治疗停药,PNTM组28例均无PNTM病加重。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the early detection of pulmonary non-tuberculous mycobacterial (PNTM) disease by CT before the initiation of molecular-targeted therapeutic drugs in patients with rheumatoid arthritis (RA) and the efficacy and safety of combined treatment with antibiotics. METHODS: Patients with RA underwent chest CT before the introduction of molecular-targeted therapies in the Further Improvement of Rheumatoid arthritis Treatment registry. The primary endpoint was the number of patients who were detected by CT as having PNTM disease, complicating RA. RESULTS: Of 4447 patients with RA who underwent chest CT, 107 had suspected PNTM disease, and 33 diagnoses were confirmed by culture. In 14 of the 33 patients, plain radiographs showed no abnormalities; PNTM disease was only observed on CT scans. The prevalence of PNTM disease in patients with RA requiring molecular-targeted treatment was six times higher than that in healthy individuals. 31 patients initiated molecular-targeted therapeutic drugs in combination with anti-NTM treatment, and 28 were followed up for 24 months. No significant difference was observed in the retention rate and RA disease activity at 24 months between the PNTM and non-PNTM groups. Coexisting PNTM disease did not affect treatment discontinuation. None of the 28 patients in the PNTM group experienced exacerbation of PNTM disease. CONCLUSION: CT screening before the initiation of molecular-targeted treatment enabled the detection of asymptomatic PNTM that was undetectable on plain radiographs. This study showed that molecular-targeted therapeutic drugs in combination with anti-NTM treatment could control the disease activity of both PNTM and RA.
引用
- Funada M, Miyazaki Y, Nakayamada S, et al. CT informs detection and treatment options in rheumatoid arthritis complicated by pulmonary non-tuberculous mycobacterial disease from the FIRST registry. RMD Open. 2024. PMID: 38866590. doi:10.1136/rmdopen-2023-004049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。